Literature DB >> 24464552

Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Hussain R Yusuf1, W Craig Hooper, Michele G Beckman, Qing C Zhang, James Tsai, Thomas L Ortel.   

Abstract

Previous research has suggested autoimmune diseases are risk factors for developing venous thromboembolism (VTE). We assessed whether having diagnoses of selected autoimmune diseases associated with antiphospholipid antibodies--autoimmune hemolytic anemia (AIHA), immune thrombocytopenic purpura (ITP), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE)--were associated with having a VTE diagnosis among US adult hospitalizations. A cross-sectional study was conducted using the 2010 Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality. VTE and autoimmune diseases were identified using International Classification of Diseases, Ninth Revision, Clinical Modification coded diagnoses information. The percentages of hospitalizations with a VTE diagnosis among all non-maternal adult hospitalizations without any of the four autoimmune diseases of interest and among those with AIHA, ITP, RA, and SLE diagnoses were 2.28, 4.46, 3.35, 2.65 and 2.77%, respectively. The adjusted odds ratios (OR) for having a diagnosis of VTE among non-maternal adult hospitalizations with diagnoses of AIHA, ITP, RA, and SLE were 1.25 [95% confidence interval (CI) 1.05-1.49], 1.20 (95% CI 1.07-1.34), 1.17 (95% CI 1.13-1.21), and 1.23 (95% CI 1.15-1.32), respectively, when compared to those without the corresponding conditions. The adjusted OR for a diagnosis of VTE associated with a diagnosis of any of the four autoimmune diseases was 1.20 (95% CI 1.16-1.24). The presence of a diagnosis of AIHA, ITP, RA, and SLE was associated with an increased likelihood of having a VTE diagnosis among the group of all non-maternal adult hospitalizations.

Entities:  

Mesh:

Year:  2014        PMID: 24464552      PMCID: PMC4477705          DOI: 10.1007/s11239-014-1050-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  31 in total

Review 1.  Epidemiology and incidence: the scope of the problem and risk factors for development of venous thromboembolism.

Authors:  Paul D Stein; Fadi Matta
Journal:  Clin Chest Med       Date:  2010-12       Impact factor: 2.878

2.  Autoimmune diseases and venous thromboembolism: a review of the literature.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

3.  Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop.

Authors:  Gary E Raskob; Roy Silverstein; Dale W Bratzler; John A Heit; Richard H White
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

Review 4.  Inflammation and coagulation in inflammatory bowel disease: The clot thickens.

Authors:  Silvio Danese; Alfredo Papa; Simone Saibeni; Alessandro Repici; Alberto Malesci; Maurizio Vecchi
Journal:  Am J Gastroenterol       Date:  2006-11-13       Impact factor: 10.864

Review 5.  Inflammation, innate immunity and blood coagulation.

Authors:  J Xu; F Lupu; C T Esmon
Journal:  Hamostaseologie       Date:  2010-01       Impact factor: 1.778

Review 6.  Venous thromboembolism: disease burden, outcomes and risk factors.

Authors:  J A Heit
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

Review 7.  Thrombosis in systemic lupus erythematosus.

Authors:  Anita Palatinus; Murray Adams
Journal:  Semin Thromb Hemost       Date:  2009-10       Impact factor: 4.180

Review 8.  Antiphospholipid syndrome.

Authors:  Diane George; Doruk Erkan
Journal:  Prog Cardiovasc Dis       Date:  2009 Sep-Oct       Impact factor: 8.194

9.  Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus.

Authors:  Chi Chiu Mok; Ling Yin Ho; Ka Lung Yu; Chi Hung To
Journal:  Clin Rheumatol       Date:  2010-01-26       Impact factor: 2.980

Review 10.  Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment.

Authors:  Grainne Murphy; Larissa Lisnevskaia; David Isenberg
Journal:  Lancet       Date:  2013-08-23       Impact factor: 79.321

View more
  9 in total

1.  Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.

Authors:  Hussain R Yusuf; W Craig Hooper; Scott D Grosse; Christopher S Parker; Sheree L Boulet; Thomas L Ortel
Journal:  Thromb Res       Date:  2014-10-22       Impact factor: 3.944

2.  Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease.

Authors:  Lauren C Bylsma; Anne Gulbech Ording; Adam Rosenthal; Buket Öztürk; Jon P Fryzek; Jaime Morales Arias; Alexander Röth; Sigbjørn Berentsen
Journal:  Blood Adv       Date:  2019-10-22

Review 3.  Epidemiology and prevention of venous thromboembolism.

Authors:  Pamela L Lutsey; Neil A Zakai
Journal:  Nat Rev Cardiol       Date:  2022-10-18       Impact factor: 49.421

4.  Dementia in a patient with autoimmune disease and hypercoagulable state worsened by COVID-19 vaccination: A case report.

Authors:  Amelia Nur Vidyanti; Mira Tamila Nurul Maulida Awaliyah; Aditya Rifqi Fauzi; Indra Sari Kusuma Harahap; Deshinta Putri Mulya
Journal:  Ann Med Surg (Lond)       Date:  2022-06-03

5.  Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®.

Authors:  Thi-Thanh Loan Nguyen; Aurore Palmaro; François Montastruc; Maryse Lapeyre-Mestre; Guillaume Moulis
Journal:  Drug Saf       Date:  2015-12       Impact factor: 5.606

Review 6.  Narrative Review of Hypercoagulability in Small-Vessel Vasculitis.

Authors:  Sophie E Claudel; Bryan M Tucker; Daniel T Kleven; James L Pirkle; Mariana Murea
Journal:  Kidney Int Rep       Date:  2020-01-13

7.  Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19: a multinational distributed network cohort analysis.

Authors:  Eng Hooi Tan; Anthony G Sena; Albert Prats-Uribe; Seng Chan You; Waheed-Ul-Rahman Ahmed; Kristin Kostka; Christian Reich; Scott L Duvall; Kristine E Lynch; Michael E Matheny; Talita Duarte-Salles; Sergio Fernandez Bertolin; George Hripcsak; Karthik Natarajan; Thomas Falconer; Matthew Spotnitz; Anna Ostropolets; Clair Blacketer; Thamir M Alshammari; Heba Alghoul; Osaid Alser; Jennifer C E Lane; Dalia M Dawoud; Karishma Shah; Yue Yang; Lin Zhang; Carlos Areia; Asieh Golozar; Martina Relcade; Paula Casajust; Jitendra Jonnagaddala; Vignesh Subbian; David Vizcaya; Lana Yh Lai; Fredrik Nyberg; Daniel R Morales; Jose D Posada; Nigam H Shah; Mengchun Gong; Arani Vivekanantham; Aaron Abend; Evan P Minty; Marc Suchard; Peter Rijnbeek; Patrick B Ryan; Daniel Prieto-Alhambra
Journal:  medRxiv       Date:  2020-11-27

Review 8.  Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review.

Authors:  Shunsuke Mori; Fumihiko Ogata; Ryusuke Tsunoda
Journal:  Clin Rheumatol       Date:  2021-09-23       Impact factor: 2.980

9.  COVID-19 in patients with autoimmune diseases: characteristics and outcomes in a multinational network of cohorts across three countries.

Authors:  Eng Hooi Tan; Anthony G Sena; Albert Prats-Uribe; Seng Chan You; Waheed-Ul-Rahman Ahmed; Kristin Kostka; Christian Reich; Scott L Duvall; Kristine E Lynch; Michael E Matheny; Talita Duarte-Salles; Sergio Fernandez Bertolin; George Hripcsak; Karthik Natarajan; Thomas Falconer; Matthew Spotnitz; Anna Ostropolets; Clair Blacketer; Thamir M Alshammari; Heba Alghoul; Osaid Alser; Jennifer C E Lane; Dalia M Dawoud; Karishma Shah; Yue Yang; Lin Zhang; Carlos Areia; Asieh Golozar; Martina Recalde; Paula Casajust; Jitendra Jonnagaddala; Vignesh Subbian; David Vizcaya; Lana Y H Lai; Fredrik Nyberg; Daniel R Morales; Jose D Posada; Nigam H Shah; Mengchun Gong; Arani Vivekanantham; Aaron Abend; Evan P Minty; Marc Suchard; Peter Rijnbeek; Patrick B Ryan; Daniel Prieto-Alhambra
Journal:  Rheumatology (Oxford)       Date:  2021-10-09       Impact factor: 7.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.